Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer Women
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of a new dose of 500mg Fulvestrant with
the standard dose of 250mg in Chinese postmenopausal women with oestrogen receptor positive
advanced breast cancer who have failed a prior endocrine treatment.